Antimicrobial resistance (AMR) is one of the top global public health and development threats. According to a 2022 article published in the Lancet, it is estimated that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to 4.95 million deaths.
BioInfect will focus on the issues surrounding the increasing threat of AMR and how it can be addressed, including working towards an integrated, unifying approach that aims to achieve optimal and sustainable health outcomes; antimicrobial stewardship; increased investment and innovation in new treatments at all stages of the drug development pipeline and ensuring ROI in the development of new antimicrobials; and the use of strategic information to inform the AMR response.